Developer docs
API playgroundTry for free, no card

Search company profiles

Cocrystal Pharma

Full company profile

uuid0002akq

Namestring
Cocrystal Pharma
Legal namestring
Cocrystal Pharma, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company headquartered in Bothell, Washington, that discovers and develops novel antiviral therapeutics using a proprietary structure-based drug discovery platform. The platform leverages Nobel Prize-winning expertise — anchored by Chief Scientist and Board Chairman Roger Kornberg (2006 Chemistry laureate) — to produce near-atomic-resolution 3D structures of inhibitor complexes, enabling the design of small molecules that target highly conserved regions of viral enzymes such as proteases and polymerases. The company's pipeline includes CDI-988, an oral pan-viral 3CL protease inhibitor in Phase 1b human challenge study for norovirus (which received FDA Fast Track designation in April 2026); CC-42344, an oral and inhaled PB2 inhibitor for influenza A whose Phase 2a study completed in late 2025 with favorable safety but undisclosed efficacy; an NIH SBIR-funded influenza A/B replication inhibitor in preclinical; and newly disclosed pan-viral inhibitors active against hantavirus, bunyavirus, and influenza.

Cocrystal has no approved products and does not generate commercial revenue. Its current revenue consists solely of non-dilutive NIH/NIAID SBIR grant income; the company reported an $8.8 million net loss in FY2025 against $7.7 million in unrestricted cash at December 31, 2025. Capital is raised primarily through small insider-led private placements (a $1.03 million round in October 2025 from directors including Phillip Frost and Fred Hassan) and public offerings, the largest being a $40 million 2021 issuance. Go-to-market upon any future approval is expected to target hospital systems, immunocompromised patient populations, military and government health programs, and pandemic preparedness stockpiles — institutional channels that the company has actively courted via presentations at MHSRS and other government-facing conferences.

The business model is a traditional clinical-stage biotech value-creation thesis: advance candidates through Phase 1–3 trials, secure regulatory designations and approvals, then either commercialize via hospital and government channels or out-license to a larger pharmaceutical partner. The company serves a global addressable market across norovirus (685 million annual cases, $60 billion economic burden), influenza (1 billion annual cases), and emerging viral threats. Leadership transitioned in June 2026 with the appointment of James Sapirstein as CEO — a commercial-stage operator with 23 prior product launches at Gilead, Bristol-Myers Squibb, and Serono — replacing the founder-led co-CEO structure and signaling preparation for a later-stage commercial inflection.

Short descriptiontext

Cocrystal Pharma (NASDAQ: COCP) is a pre-revenue clinical-stage biotech developing oral antiviral drug candidates for norovirus, influenza, and coronaviruses using a proprietary structure-based drug discovery platform anchored by Nobel laureate Roger Kornberg, targeting hospitals and government health programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBothell, United States
HQ citystring
Bothell
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral therapeutics, structure-based drug discovery, clinical-stage biotechnology, influenza treatment, norovirus treatment
Industry3 codes
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antiviral Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1NIH/NIAID SBIR Grants
TypeOthers
Description

Non-dilutive grant funding from National Institutes of Health Small Business Innovation Research awards supporting specific research programs

globenewswire.com
2Future Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company planning to commercialize antiviral therapeutics through traditional pharmaceutical sales channels upon regulatory approval

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cocrystal Pharma is a clinical-stage biotechnology company that discovers and develops novel broad-spectrum antiviral therapeutics using a proprietary structure-based drug discovery platform. Its lead candidates include CDI-988, an oral pan-viral 3CL protease inhibitor for norovirus and coronavirus infections, and CC-42344, an oral and inhaled PB2 inhibitor for pandemic and seasonal influenza A. Additional programs target hepatitis C, rhinovirus, hantavirus, and bunyavirus.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IC50 <50 nM against hantaan virus (hantavirus) replication enzyme
+3 more records
Product overview1 text field

Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics targeting viral replication processes. The company's portfolio includes multiple drug candidates at various clinical stages: CDI-988 (oral pan-viral protease inhibitor for norovirus and coronavirus, Phase 1b), CC-42344 oral and inhaled formulations (influenza A PB2 inhibitor, Phase 2a completed), an NIH-funded influenza A/B replication inhibitor program, CDI-31244 (hepatitis C NS5B inhibitor), and novel pan-viral hantavirus inhibitors in discovery. These candidates are developed using the company's proprietary structure-based drug discovery platform technology that provides near-atomic resolution 3D structural data to guide drug design.

Product and service6 records
1CDI-988
CategoryDrug candidate (antiviral)
Description

First oral pan-viral protease inhibitor targeting the 3CL protease for treatment and prophylaxis of norovirus and coronavirus infections. Currently in Phase 1b human challenge study at Emory University with FDA Fast Track designation granted in April 2026.

2CC-42344 (Oral)
CategoryDrug candidate (antiviral)
Description

Novel oral PB2 inhibitor for treatment of pandemic and seasonal influenza A strains, including strains resistant to Tamiflu and Xofluza. Phase 2a study completed.

3CC-42344 (Inhaled)
CategoryDrug candidate (antiviral)
Description

Dry powder inhalation formulation of CC-42344 for prophylaxis and treatment of pandemic and seasonal influenza A. GLP toxicology studies completed.

4Influenza A/B Replication Inhibitor
CategoryDrug candidate (antiviral)
Description

Novel broad-spectrum lead candidate targeting the influenza A/B polymerase complex. NIH SBIR Phase I funded program in lead discovery.

5CDI-31244
CategoryDrug candidate (antiviral)
Description

Pan-genotypic NS5B non-nucleoside inhibitor for treatment of chronic hepatitis C. Previously in preclinical and clinical studies.

6Pan-Viral Replication Inhibitors (Hantavirus/Bunyavirus Program)
CategoryDrug candidate (antiviral)
Description

Novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza with in vitro potency data showing IC50 <50 nM against hantaan virus replication enzyme.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Collaboration to conduct Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment. Emory provides clinical research infrastructure, virology expertise, and norovirus challenge model capabilities. Study NCT07198139 enrolling up to 40 healthy adults aged 18-49.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Collaboration partner for Phase 1b norovirus challenge study with CDI-988, providing clinical research support alongside Emory University.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-08-08
Description

Partnership for Phase 2 trial of antiviral flu treatment candidate CC-42344. hVIVO conducted human challenge studies in the United Kingdom following MHRA authorization.

4NIAID (COVID-19 Protease Inhibitors)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-06-02
Description

Expanded partnership for COVID-19 protease inhibitors development. NIAID collaboration supporting preclinical and clinical advancement of coronavirus antiviral candidates.

cocrystalpharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing small-molecule antivirals for RSV, hepatitis B, and other viral infections — comparable in size, modality (oral small molecules), and clinical-stage profile to Cocrystal.

TypeDirect peer
Description

Clinical-stage immunology company developing antiviral therapeutics (including influenza and coronavirus programs) using a platform approach — closely comparable to Cocrystal's structure-based discovery model targeting multiple viral families.

TypeDirect peer
Description

Clinical-stage biotech developing oral direct-acting antivirals for serious viral infections including HCV and SARS-CoV-2, with a Phase 2-ready pipeline. Directly comparable to Cocrystal's oral antiviral small-molecule approach.

TypeDirect peer
Description

Clinical-stage antiviral company developing oral protease inhibitors for SARS-CoV-2 and other viral diseases using structure-based design — same drug discovery paradigm and target class (viral proteases) as Cocrystal's CDI-988.

TypeEmerging player
Description

Clinical-stage company developing vaccines and therapeutics for infectious diseases including influenza and coronaviruses — overlapping therapeutic indications but using RNA-based modality rather than Cocrystal's small-molecule approach.

TypeBroad incumbent
Description

Japanese pharmaceutical company that developed Xofluza (baloxavir marboxil), a leading single-dose influenza antiviral. CC-42344 targets the same indication and must differentiate against this entrenched competitor.

TypeBroad incumbent
Description

Global antiviral leader with franchises in HIV, hepatitis C (Sovaldi/Harvoni), and remdesivir for COVID-19. Cocrystal's new CEO James Sapirstein previously held senior commercial roles at Gilead, illustrating the bench-strength overlap and competitive benchmark for any antiviral launch.

TypeBroad incumbent
Description

Developer of Tamiflu (oseltamivir), the leading oral influenza antiviral. Represents the entrenched standard-of-care competitor that Cocrystal's influenza program must displace.

TypeBroad incumbent
Description

Large commercial-stage biotech with established mRNA vaccine franchises for COVID-19 and influenza. Represents the modality-agnostic competitive threat for pandemic preparedness stockpiling dollars.

10ContraVir Pharmaceuticals
TypeOthers
Description

Antiviral-focused company where incoming Cocrystal CEO James Sapirstein previously served as CEO. Represents a peer career trajectory and historical reference point for Cocrystal's hepatitis and antiviral development approach.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cocrystal Pharma

Antiviral Therapeuticscocrystalpharma.com

Cocrystal Pharma (NASDAQ: COCP) is a pre-revenue clinical-stage biotech developing oral antiviral drug candidates for norovirus, influenza, and coronaviruses using a proprietary structure-based drug discovery platform anchored by Nobel laureate Roger Kornberg, targeting hospitals and government health programs.

What Cocrystal Pharma does

Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company headquartered in Bothell, Washington, that discovers and develops novel antiviral therapeutics using a proprietary structure-based drug discovery platform. The platform leverages Nobel Prize-winning expertise — anchored by Chief Scientist and Board Chairman Roger Kornberg (2006 Chemistry laureate) — to produce near-atomic-resolution 3D structures of inhibitor complexes, enabling the design of small molecules that target highly conserved regions of viral enzymes such as proteases and polymerases. The company's pipeline includes CDI-988, an oral pan-viral 3CL protease inhibitor in Phase 1b human challenge study for norovirus (which received FDA Fast Track designation in April 2026); CC-42344, an oral and inhaled PB2 inhibitor for influenza A whose Phase 2a study completed in late 2025 with favorable safety but undisclosed efficacy; an NIH SBIR-funded influenza A/B replication inhibitor in preclinical; and newly disclosed pan-viral inhibitors active against hantavirus, bunyavirus, and influenza.

Cocrystal has no approved products and does not generate commercial revenue. Its current revenue consists solely of non-dilutive NIH/NIAID SBIR grant income; the company reported an $8.8 million net loss in FY2025 against $7.7 million in unrestricted cash at December 31, 2025. Capital is raised primarily through small insider-led private placements (a $1.03 million round in October 2025 from directors including Phillip Frost and Fred Hassan) and public offerings, the largest being a $40 million 2021 issuance. Go-to-market upon any future approval is expected to target hospital systems, immunocompromised patient populations, military and government health programs, and pandemic preparedness stockpiles — institutional channels that the company has actively courted via presentations at MHSRS and other government-facing conferences.

The business model is a traditional clinical-stage biotech value-creation thesis: advance candidates through Phase 1–3 trials, secure regulatory designations and approvals, then either commercialize via hospital and government channels or out-license to a larger pharmaceutical partner. The company serves a global addressable market across norovirus (685 million annual cases, $60 billion economic burden), influenza (1 billion annual cases), and emerging viral threats. Leadership transitioned in June 2026 with the appointment of James Sapirstein as CEO — a commercial-stage operator with 23 prior product launches at Gilead, Bristol-Myers Squibb, and Serono — replacing the founder-led co-CEO structure and signaling preparation for a later-stage commercial inflection.

Cocrystal Pharma firmographics

Firmographics
Name
Cocrystal Pharma
Legal name
Cocrystal Pharma, Inc.
Website
https://cocrystalpharma.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Cocrystal Pharma (NASDAQ: COCP) is a pre-revenue clinical-stage biotech developing oral antiviral drug candidates for norovirus, influenza, and coronaviruses using a proprietary structure-based drug discovery platform anchored by Nobel laureate Roger Kornberg, targeting hospitals and government health programs.
Ownership category
akta.pro rank

Cocrystal Pharma industry classification

Industry
Product category
Antiviral Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Antiviral therapeutics
  • Structure-based drug discovery
  • Clinical-stage biotechnology
  • Influenza treatment
  • Norovirus treatment

Where Cocrystal Pharma is headquartered

Location

Headquarters

HQ city
Bothell
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cocrystal Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. NIH/NIAID SBIR Grants: Non-dilutive grant funding from National Institutes of Health Small Business Innovation Research awards supporting specific research programs
  2. Future Product Revenue: Pre-revenue clinical-stage company planning to commercialize antiviral therapeutics through traditional pharmaceutical sales channels upon regulatory approval

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Cocrystal Pharma product offering

Product offering

Core offering

Cocrystal Pharma is a clinical-stage biotechnology company that discovers and develops novel broad-spectrum antiviral therapeutics using a proprietary structure-based drug discovery platform. Its lead candidates include CDI-988, an oral pan-viral 3CL protease inhibitor for norovirus and coronavirus infections, and CC-42344, an oral and inhaled PB2 inhibitor for pandemic and seasonal influenza A. Additional programs target hepatitis C, rhinovirus, hantavirus, and bunyavirus.

Product overview

Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics targeting viral replication processes. The company's portfolio includes multiple drug candidates at various clinical stages: CDI-988 (oral pan-viral protease inhibitor for norovirus and coronavirus, Phase 1b), CC-42344 oral and inhaled formulations (influenza A PB2 inhibitor, Phase 2a completed), an NIH-funded influenza A/B replication inhibitor program, CDI-31244 (hepatitis C NS5B inhibitor), and novel pan-viral hantavirus inhibitors in discovery. These candidates are developed using the company's proprietary structure-based drug discovery platform technology that provides near-atomic resolution 3D structural data to guide drug design.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDI-988 First oral pan-viral protease inhibitor targeting the 3CL protease for treatment and prophylaxis of norovirus and coronavirus infections. Currently in Phase 1b human challenge study at Emory University with FDA Fast Track designation granted in April 2026.
  • CC-42344 (Oral) Novel oral PB2 inhibitor for treatment of pandemic and seasonal influenza A strains, including strains resistant to Tamiflu and Xofluza. Phase 2a study completed.
  • CC-42344 (Inhaled) Dry powder inhalation formulation of CC-42344 for prophylaxis and treatment of pandemic and seasonal influenza A. GLP toxicology studies completed.
  • Influenza A/B Replication Inhibitor Novel broad-spectrum lead candidate targeting the influenza A/B polymerase complex. NIH SBIR Phase I funded program in lead discovery.
  • CDI-31244 Pan-genotypic NS5B non-nucleoside inhibitor for treatment of chronic hepatitis C. Previously in preclinical and clinical studies.
  • Pan-Viral Replication Inhibitors (Hantavirus/Bunyavirus Program) Novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza with in vitro potency data showing IC50 <50 nM against hantaan virus replication enzyme.

Quantifiable outcome

  • IC50 <50 nM against hantaan virus (hantavirus) replication enzyme
  • +3 more outcomes

Companies that use Cocrystal Pharma

Customer profile

Segments4 records

Ideal customer profiles3 records

Cocrystal Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cocrystal Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Emory University School of MedicinecoreStrategic or Co-development Partner · 9 March 2026Collaboration to conduct Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment. Emory provides clinical research infrastructure, virology expertise, and norovirus challenge model capabilities. Study NCT07198139 enrolling up to 40 healthy adults aged 18-49.
  • University of North CarolinacoreStrategic or Co-development Partner · 9 March 2026Collaboration partner for Phase 1b norovirus challenge study with CDI-988, providing clinical research support alongside Emory University.
  • hVIVOminorStrategic or Co-development Partner · 8 August 2022Partnership for Phase 2 trial of antiviral flu treatment candidate CC-42344. hVIVO conducted human challenge studies in the United Kingdom following MHRA authorization.
  • NIAID (COVID-19 Protease Inhibitors)minorStrategic or Co-development Partner · 2 June 2022Expanded partnership for COVID-19 protease inhibitors development. NIAID collaboration supporting preclinical and clinical advancement of coronavirus antiviral candidates.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Cocrystal Pharma competitors and assessment

Company assessment

Direct peers

  • Enanta Pharmaceuticals: Clinical-stage biotech developing small-molecule antivirals for RSV, hepatitis B, and other viral infections — comparable in size, modality (oral small molecules), and clinical-stage profile to Cocrystal.
  • Vir Biotechnology: Clinical-stage immunology company developing antiviral therapeutics (including influenza and coronavirus programs) using a platform approach — closely comparable to Cocrystal's structure-based discovery model targeting multiple viral families.
  • Atea Pharmaceuticals: Clinical-stage biotech developing oral direct-acting antivirals for serious viral infections including HCV and SARS-CoV-2, with a Phase 2-ready pipeline. Directly comparable to Cocrystal's oral antiviral small-molecule approach.
  • Pardes Biosciences: Clinical-stage antiviral company developing oral protease inhibitors for SARS-CoV-2 and other viral diseases using structure-based design — same drug discovery paradigm and target class (viral proteases) as Cocrystal's CDI-988.

Emerging players

  • Arcturus Therapeutics: Clinical-stage company developing vaccines and therapeutics for infectious diseases including influenza and coronaviruses — overlapping therapeutic indications but using RNA-based modality rather than Cocrystal's small-molecule approach.

Broad incumbents

  • Shionogi: Japanese pharmaceutical company that developed Xofluza (baloxavir marboxil), a leading single-dose influenza antiviral. CC-42344 targets the same indication and must differentiate against this entrenched competitor.
  • Gilead Sciences: Global antiviral leader with franchises in HIV, hepatitis C (Sovaldi/Harvoni), and remdesivir for COVID-19. Cocrystal's new CEO James Sapirstein previously held senior commercial roles at Gilead, illustrating the bench-strength overlap and competitive benchmark for any antiviral launch.
  • Roche: Developer of Tamiflu (oseltamivir), the leading oral influenza antiviral. Represents the entrenched standard-of-care competitor that Cocrystal's influenza program must displace.
  • Moderna: Large commercial-stage biotech with established mRNA vaccine franchises for COVID-19 and influenza. Represents the modality-agnostic competitive threat for pandemic preparedness stockpiling dollars.

Others

  • ContraVir Pharmaceuticals: Antiviral-focused company where incoming Cocrystal CEO James Sapirstein previously served as CEO. Represents a peer career trajectory and historical reference point for Cocrystal's hepatitis and antiviral development approach.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cocrystal Pharma social profiles

Digital presence

Cocrystal Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cocrystal Pharma leadership team

Management profile

Number of profiles

Profiles9 records

Cocrystal Pharma funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cocrystal Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cocrystal Pharma

What does Cocrystal Pharma do?

Cocrystal Pharma is a clinical-stage biotechnology company that discovers and develops novel broad-spectrum antiviral therapeutics using a proprietary structure-based drug discovery platform. Its lead candidates include CDI-988, an oral pan-viral 3CL protease inhibitor for norovirus and coronavirus infections, and CC-42344, an oral and inhaled PB2 inhibitor for pandemic and seasonal influenza A. Additional programs target hepatitis C, rhinovirus, hantavirus, and bunyavirus.

Is Cocrystal Pharma a public or private company?

Cocrystal Pharma is a public company. It is classified as public and is currently operating.

When was Cocrystal Pharma founded?

Cocrystal Pharma was founded in 2014. It employs 11 to 50 people.

Where is Cocrystal Pharma based?

Cocrystal Pharma is headquartered in Bothell, United States, in the North America region.

How does Cocrystal Pharma make money?

Two revenue lines are on record. NIH/NIAID SBIR Grants are the primary driver. The others are future Product Revenue.

Who are Cocrystal Pharma's main competitors?

Direct peers on record are Enanta Pharmaceuticals, Vir Biotechnology, Atea Pharmaceuticals and Pardes Biosciences. Arcturus Therapeutics is listed as an emerging player. Broad incumbents are Shionogi, Gilead Sciences, Roche and Moderna. ContraVir Pharmaceuticals is listed as an others.

Does Cocrystal Pharma have an API?

No public API is recorded for Cocrystal Pharma.

What industry is Cocrystal Pharma in?

Cocrystal Pharma's product category is Antiviral Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerCocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Cocrystal Pharma reported a Q3 net loss of $3.44 million, up from $2.05 million a year ago, and a nine-month net loss of $8.91 million, up from $6.41 million. Basic and diluted loss per share from continuing operations were $0.20 and $0.59, respectively, compared to $0.19 and $0.61 a year ago.The future of tradingCocrystal Pharma Appoints Carol Brosgart to Board of DirectorsCocrystal Pharma appointed Carol Brosgart to its board of directors, effective August 12, 2026. Brosgart spent over a decade at Gilead Sciences, helping develop antiviral therapies Viread and Hepsera.TradingViewCocrystal Pharma, Inc. (COCP) Q3 Net Loss Rises to $3.4M; Phase 1b Dosing CompleteCocrystal Pharma reported a Q3 2026 net loss of $3.4 million, up from $2.0 million a year earlier, with revenue of $105,000. The company completed dosing in its 32-person Phase 1b norovirus challenge study, with preliminary efficacy results expected in late 2026. It also closed a $5 million private placement with OPKO Health.Defense WorldXeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head ContrastXeris Biopharma outperforms Cocrystal Pharma on 9 of 14 comparison factors, including higher revenue, lower P/E, and stronger analyst ratings. Xeris has a consensus price target of $13.20, implying 29.79% upside, while Cocrystal's beta is 1.48 versus Xeris's 0.53.Markets DailyBristol Myers Squibb (NYSE:BMY) versus Cocrystal Pharma (NASDAQ:COCP) Financial ReviewBristol Myers Squibb outperforms Cocrystal Pharma on 12 of 15 financial factors, including profitability and analyst ratings. Bristol Myers Squibb has higher revenue and earnings, while Cocrystal Pharma trades at a lower price-to-earnings ratio. Bristol Myers Squibb's consensus target price is $67.06, implying 6.70% upside.YahooCocrystal Pharma: The Strategic Reset Investors May Be MissingCocrystal Pharma appointed James Sapirstein as CEO, replacing its co-CEO structure on June 3, 2026, with Sam Lee as President and Jim Martin as CFO. The company has a drug discovery platform for broad-spectrum antivirals targeting norovirus, influenza, coronaviruses, and hepatitis C. The leadership change aims to align the board and raise capital for commercialization.Investing.comCocrystal Pharma appoints Carol L. Brosgart to board of directors By Investing.comCocrystal Pharma appointed Carol L. Brosgart to its board of directors effective August 12, 2026, following recent leadership changes that installed James Sapirstein as CEO. The appointment occurs while the biotech company faces financial headwinds, having posted a loss of $0.76 per share over the last twelve months with a market capitalization of $20.8 million.BioSpaceCocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsCocrystal Pharma appointed Carol Brosgart, MD, to its board of directors, effective August 12, 2026. She brings decades of antiviral therapy experience, including FDA approvals of Viread and Hepsera. The appointment aims to guide clinical development of CDI-988 for norovirus and the broader antiviral pipeline.Investing.comCocrystal Pharma appoints Carol Brosgart to board of directors By Investing.comCocrystal Pharma appointed Dr. Carol Brosgart to its Board of Directors, effective August 12. Dr. Brosgart brings extensive experience in antiviral therapy and epidemiology, having previously served at Gilead Sciences and various other biotechnology firms. Cocrystal Pharma is currently advancing the clinical development of CDI-988 for norovirus treatment.Quiver QuantitativeCocrystal Pharma Appoints Carol Brosgart, M.D. to Board of Directors | COCP Stock NewsCocrystal Pharma appointed Dr. Carol Brosgart to its Board of Directors effective August 12, 2026, to leverage her extensive expertise in antiviral drug development and strategy. Her addition is expected to support the clinical advancement of the company's norovirus candidate CDI-988 and broader pipeline initiatives.